Antibody-Drug Conjugates (ADCs): A Novel Therapy for Triple-Negative Breast Cancer (TNBC)

被引：5
作者：
Gupta, Gaurav [1 ,2 ]
Hussain, Md Sadique [3 ]
Pant, Kumud [4 ,5 ]
Ali, Haider [6 ,7 ]
Thapa, Riya [3 ]
Bhat, Asif Ahmad [3 ]
机构：
[1] Chitkara Univ, Chitkara Coll Pharm, Rajpura, Chandigarh, India
[2] Ajman Univ, Ctr Med & Bioallied Hlth Sci Res, Ajman, U Arab Emirates
[3] Uttaranchal Univ, Uttaranchal Inst Pharmaceut Sci, Dehra Dun 248007, Uttarakhand, India
[4] Graph Era Deemed Univ, Clement Town Dehradun 248002, India
[5] Graph Era Hill Univ, Sch Pharmaceut Sci, Clement Town Dehradun 248002, India
[6] Saveetha Univ, Saveetha Inst Med & Tech Sci, Saveetha Med Coll, Ctr Global Hlth Res, Chennai, India
[7] Kyrgyz State Med Coll, Dept Pharmacol, Bishkek, Kyrgyzstan
来源：
CURRENT CANCER DRUG TARGETS | 2025年 / 25卷 / 02期
关键词：
Antibody-drug conjugates; triple-negative breast cancer; Sacituzumab govitecan; Trop2; antigen; clinical trial;
D O I：
10.2174/0115680096343056240828190900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：108 / 112
页数：5
相关论文
共 50 条
  • [1] Breaking barriers in triple negative breast cancer (TNBC) - Unleashing the power of antibody-drug conjugates (ADCs)
    Dri, Arianna
    Arpino, Grazia
    Bianchini, Giampaolo
    Curigliano, Giuseppe
    Danesi, Romano
    De Laurentiis, Michelino
    Del Mastro, Lucia
    Fabi, Alessandra
    Generali, Daniele
    Gennari, Alessandra
    Guarneri, Valentina
    Santini, Daniele
    Simoncini, Edda
    Zamagni, Claudio
    Puglisi, Fabio
    CANCER TREATMENT REVIEWS, 2024, 123
  • [2] Novel antibody-drug conjugates for triple negative breast cancer
    Nagayama, Aiko
    Vidula, Neelima
    Ellisen, Leif
    Bardia, Aditya
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] Antibody-Drug Conjugates in Triple Negative Breast Cancer
    Keskinkilic, Merve
    Sacks, Ruth
    CLINICAL BREAST CANCER, 2024, 24 (03) : 163 - 174
  • [4] Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates
    Kaboli, Parham Jabbarzadeh
    Shabani, Shima
    Sharma, Sagar
    Nasr, Minoo Partovi
    Yamaguchi, Hirohito
    Hung, Mien-Chie
    AMERICAN JOURNAL OF CANCER RESEARCH, 2022, 12 (04): : 1671 - 1685
  • [5] Advances in antibody-drug conjugates in the treatment of advanced triple-negative breast cancer: a narrative review
    Jiang, Kuikui
    Wang, Shusen
    TRANSLATIONAL BREAST CANCER RESEARCH, 2025, 6
  • [6] Unveiling the antibody-drug conjugates portfolio in battling Triple-negative breast cancer: Therapeutic trends and Future horizon
    Khadela, Avinash
    Soni, Shruti
    Shah, Aayushi C.
    Pandya, Aanshi J.
    Megha, Kaivalya
    Kothari, Nirjari
    Avinash, C. B.
    MEDICAL ONCOLOGY, 2022, 40 (01)
  • [7] Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives
    Sawant, Sanjana
    Naik, Gaurav Gopal
    Sahu, Alakh N.
    Jagtap, Vijay A.
    MEDICAL ONCOLOGY, 2024, 41 (12)
  • [8] Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer
    Schipilliti, Francesca Matilde
    Drittone, Denise
    Mazzuca, Federica
    La Forgia, Daniele
    Guven, Deniz Can
    Rizzo, Alessandro
    HELIYON, 2024, 10 (07)
  • [9] Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy
    Si, Yingnan
    Xu, Yuanxin
    Guan, JiaShiung
    Chen, Kai
    Kim, Seulhee
    Yang, Eddy S.
    Zhou, Lufang
    Liu, Xiaoguang Margaret
    ENGINEERING IN LIFE SCIENCES, 2021, 21 (1-2): : 37 - 44
  • [10] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
12345